Skip to content

Prognostic value of BANCR in predicting lymph node metastasis and prognosis of resectable pancreatic ductal adenocarcinoma

Prognostic value of BANCR in predicting lymph node metastasis and prognosis of resectable pancreatic ductal adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062674
Enrollment
Unknown
Registered
2022-08-15
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic caner

Interventions

BANCR(+):Radical excision
BANCR(-):Radical excision

Sponsors

Beijing Luhe Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with newly diagnosed pancreatic cancer who did not receive any preoperative surgery, radiation, chemotherapy, immunosuppression, or molecular targeting therapy; 2. All patients with resectable pancreatic cancer were evaluated by preoperative enhanced CT; 3. Two pathologists were independently diagnosed as pancreatic ductal adenocarcinoma.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors (such as lung cancer, stomach cancer, colorectal cancer, etc.); 2. Patients with other contraindicated diseases such as serious circulatory and metabolic diseases; 3. Do not agree to participate in this project and quit the research halfway; 4. Abnormal WBC count in peripheral blood caused by infection symptoms before surgery, which failed to return to normal after anti-inflammatory treatment; 5. Patients who failed to undergo intraoperative radical resection of pancreatic cancer; 6. Patients with serious complications after surgery; 7. Postoperative death due to non-pancreatic cancer related causes; 8. Tumors of other sources occurred during reexamination; 9. Incomplete clinicopathological data and follow-up data.

Design outcomes

Primary

MeasureTime frame
The positive rate of pathological lymph node metastasis;Overall Survival;Disease Free Survival;Level of BANCR in peripheral blood;Level of BANCR in tumor tissue;

Secondary

MeasureTime frame
Level of CA19-9;Lymph node positive rate on enhanced CT;

Countries

China

Contacts

Public ContactHan Wei

Beijing Luhe Hospital, Capital Medical University

dr-han1972@mail.ccmu.edu.cn+86 18501933816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026